Keytruda
Keytruda Receives Traditional Approval for Some Patients With HER2-Positive Gastric or GEJ Adenocarcinoma
The FDA has granted traditional approval to Keytruda with trastuzumab, fluoropyrimidine- and platinum-containing ...
MARCH 20, 2025
FDA Approves Keytruda With Chemo for Primary Advanced or Recurrent Endometrial Carcinoma
The FDA has approved Keytruda with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult ...
JUNE 18, 2024
Keytruda With Chemoradiotherapy Approved for FIGO 2014 Stage III-IVA Cervical Cancer
The FDA approved Keytruda with chemoradiotherapy for patients with FIGO 2014 stage III to IVA cervical cancer.
JANUARY 19, 2024
FDA Approves Neoadjuvant/Adjuvant Keytruda for Resectable NSCLC
The FDA approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, ...
OCTOBER 17, 2023
Keytruda Approved for Adjuvant Treatment of Certain Kinds of NSCLC
The FDA has approved Keytruda for adjuvant treatment following resection and platinum-based chemotherapy for ...
FEBRUARY 3, 2023
Pharmacokinetics May Help Optimize Dosing of ICIs
Flat and extended-interval dosing of some immune checkpoint inhibitor (ICI) drugs can be used in certain ...
APRIL 14, 2022
Pembrolizumab Newly Indicated to Treat Advanced Endometrial Carcinoma
The FDA approved pembrolizumab (Keytruda, Merck) for the treatment of patients with microsatellite instability?high ...
MARCH 23, 2022
Pembrolizumab After Resection of Stage II Melanoma Reduces Recurrence Risk
In patients with resected stage IIB or IIC melanoma, adjuvant pembrolizumab (Keytruda, Merck) significantly reduces ...
JANUARY 11, 2022
Keytruda Gains Approval to Treat Patients With RCC After Nephrectomy
The FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma ...
NOVEMBER 29, 2021
Keytruda Approved to Treat PD-L1-Positive Cervical Cancer
The FDA approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for ...
OCTOBER 22, 2021
Keytruda Approved to Treat High-Risk, Early-Stage TNBC
The FDA approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage triple-negative breast cancer (TNBC) in ...
AUGUST 10, 2021
Keytruda Gains Indication for Locally Advanced Squamous Cell Carcinoma
The FDA approved an additional indication for pembrolizumab (Keytruda, Merck)—monotherapy for locally ...
JULY 13, 2021
